Aptar Pharma Supports Development of Next-Gen Nasal Spray
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy ATR?
Source: Newsfilter
- Clinical Study Progress: Aptar Pharma's UDS Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA-051, aimed at evaluating its potential to protect against symptomatic viral respiratory infections, marking a significant innovation effort in respiratory health.
- Technical Advantages: The UDS system is designed to deliver a single, precise dose of dry powder, ensuring consistent performance in clinical development settings, thereby enhancing drug reliability and patient experience, which is crucial for market competitiveness.
- Moisture Protection: The nasal delivery system features Aptar CSP Technologies' innovative container closure system, incorporating 3-Phase Activ-Polymer™ technology to effectively protect the powder formulation from moisture, ensuring stability and efficacy to meet market demands for high-quality drug delivery.
- Strategic Collaboration: The partnership between Aptar Pharma and ENA Respiratory not only showcases its leadership in drug delivery technologies but also reflects the company's strategic direction towards developing non-vaccine approaches to address respiratory diseases, further solidifying its influence in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 121.990
Low
133.00
Averages
145.33
High
156.00
Current: 121.990
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Wall Street Rating Updates on Friday
- Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
- Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
- Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
- Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
See More
Aptar Pharma Supports Development of Next-Gen Nasal Spray
- Clinical Study Progress: Aptar Pharma's UDS Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA-051, aimed at evaluating its potential to protect against symptomatic viral respiratory infections, marking a significant innovation effort in respiratory health.
- Technical Advantages: The UDS system is designed to deliver a single, precise dose of dry powder, ensuring consistent performance in clinical development settings, thereby enhancing drug reliability and patient experience, which is crucial for market competitiveness.
- Moisture Protection: The nasal delivery system features Aptar CSP Technologies' innovative container closure system, incorporating 3-Phase Activ-Polymer™ technology to effectively protect the powder formulation from moisture, ensuring stability and efficacy to meet market demands for high-quality drug delivery.
- Strategic Collaboration: The partnership between Aptar Pharma and ENA Respiratory not only showcases its leadership in drug delivery technologies but also reflects the company's strategic direction towards developing non-vaccine approaches to address respiratory diseases, further solidifying its influence in the pharmaceutical industry.
See More
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
- Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
- Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
- Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
- Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
See More
AptarGroup Appoints New CEO Gael Touya
- Executive Change: AptarGroup announced that Gael Touya will become president and CEO effective September 1, 2026, succeeding Stephan B. Tanda, who has held the position since 2017, indicating a significant leadership shift for the company.
- Transition Support: Stephan B. Tanda will continue to work as an advisor until the end of the year to ensure a smooth transition for new CEO Gael Touya, helping the company maintain stability as it enters its next growth phase.
- Board Appointment: On the same day Gael Touya assumes his role, he will also be appointed as a director by the board, further solidifying his leadership position within the company and reflecting confidence in his future direction.
- Retirement Plans: Stephan B. Tanda intends to retire from the board by the end of 2026, suggesting a shift in leadership style and strategic direction that could impact the company's long-term growth and market performance.
See More
Aptar Supports LTR Pharma's Intranasal Therapy Development
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
See More
Energy Stocks Flash Momentum Warning for Investors
- Momentum Indicator Warning: As of March 2, 2026, two stocks in the energy sector are signaling momentum warnings, particularly with Relative Strength Index (RSI) values exceeding 70, indicating potential overbought conditions that investors should heed.
- Nordic American Tankers Performance: Nordic American Tankers (NYSE:NAT) reported disappointing quarterly results on February 26, and despite a 37% stock price increase over the past month, its RSI stands at 93.8, suggesting a risk of correction due to overvaluation.
- Price Action Analysis: NAT's shares rose 6.1% to close at $5.73 on Friday, showing strong short-term performance; however, the high RSI indicates potential price adjustments ahead, prompting investors to monitor market developments closely.
- Tsakos Energy Navigation Overview: Tsakos Energy Navigation (NYSE:TEN) is also under scrutiny, with strong momentum scores, although specific data is not disclosed, investors should consider overall market trends and individual stock performance.
See More
Key Wall Street Rating Updates on Friday
- Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
- Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
- Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
- Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
See More
Aptar Pharma Supports Development of Next-Gen Nasal Spray
- Clinical Study Progress: Aptar Pharma's UDS Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA-051, aimed at evaluating its potential to protect against symptomatic viral respiratory infections, marking a significant innovation effort in respiratory health.
- Technical Advantages: The UDS system is designed to deliver a single, precise dose of dry powder, ensuring consistent performance in clinical development settings, thereby enhancing drug reliability and patient experience, which is crucial for market competitiveness.
- Moisture Protection: The nasal delivery system features Aptar CSP Technologies' innovative container closure system, incorporating 3-Phase Activ-Polymer™ technology to effectively protect the powder formulation from moisture, ensuring stability and efficacy to meet market demands for high-quality drug delivery.
- Strategic Collaboration: The partnership between Aptar Pharma and ENA Respiratory not only showcases its leadership in drug delivery technologies but also reflects the company's strategic direction towards developing non-vaccine approaches to address respiratory diseases, further solidifying its influence in the pharmaceutical industry.
See More
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
- Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
- Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
- Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
- Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
See More
AptarGroup Appoints New CEO Gael Touya
- Executive Change: AptarGroup announced that Gael Touya will become president and CEO effective September 1, 2026, succeeding Stephan B. Tanda, who has held the position since 2017, indicating a significant leadership shift for the company.
- Transition Support: Stephan B. Tanda will continue to work as an advisor until the end of the year to ensure a smooth transition for new CEO Gael Touya, helping the company maintain stability as it enters its next growth phase.
- Board Appointment: On the same day Gael Touya assumes his role, he will also be appointed as a director by the board, further solidifying his leadership position within the company and reflecting confidence in his future direction.
- Retirement Plans: Stephan B. Tanda intends to retire from the board by the end of 2026, suggesting a shift in leadership style and strategic direction that could impact the company's long-term growth and market performance.
See More
Aptar Supports LTR Pharma's Intranasal Therapy Development
- Clinical Study Progress: AptarGroup's nasal delivery system is utilized in LTR Pharma's Phase II clinical study of SPONTAN®, reflecting the company's ongoing commitment to supporting intranasal drug delivery technologies, which is expected to drive the development of innovative therapies.
- First Patient Dosing: LTR Pharma recently announced the dosing of the first patients in the SPONTAN® study, which evaluates the safety and tolerability of the rapid-acting intranasal spray, further advancing clinical development and regulatory pathways.
- Strengthened Technical Collaboration: Aptar's nasal spray platform is a multidose delivery system designed to provide accurate and consistent dosing of prescription drugs, enhancing Aptar's position as a trusted partner in advancing complex intranasal therapies through robust regulatory and technical expertise.
- Strategic Investment Value: LTR Pharma's Executive Chairman noted that partnering with Aptar provides a solid foundation for their clinical and regulatory pathway, emphasizing the critical role of reliable nasal drug delivery in their development strategy, which may enhance market competitiveness.
See More
Energy Stocks Flash Momentum Warning for Investors
- Momentum Indicator Warning: As of March 2, 2026, two stocks in the energy sector are signaling momentum warnings, particularly with Relative Strength Index (RSI) values exceeding 70, indicating potential overbought conditions that investors should heed.
- Nordic American Tankers Performance: Nordic American Tankers (NYSE:NAT) reported disappointing quarterly results on February 26, and despite a 37% stock price increase over the past month, its RSI stands at 93.8, suggesting a risk of correction due to overvaluation.
- Price Action Analysis: NAT's shares rose 6.1% to close at $5.73 on Friday, showing strong short-term performance; however, the high RSI indicates potential price adjustments ahead, prompting investors to monitor market developments closely.
- Tsakos Energy Navigation Overview: Tsakos Energy Navigation (NYSE:TEN) is also under scrutiny, with strong momentum scores, although specific data is not disclosed, investors should consider overall market trends and individual stock performance.
See More
